GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Beneish M-Score

Brii Biosciences (HKSE:02137) Beneish M-Score : 103.06 (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 103.06 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Brii Biosciences's Beneish M-Score or its related term are showing as below:

HKSE:02137' s Beneish M-Score Range Over the Past 10 Years
Min: 103.06   Med: 103.06   Max: 103.06
Current: 103.06

During the past 5 years, the highest Beneish M-Score of Brii Biosciences was 103.06. The lowest was 103.06. And the median was 103.06.


Brii Biosciences Beneish M-Score Historical Data

The historical data trend for Brii Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Beneish M-Score Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - - 103.06

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only - - - - 103.06

Competitive Comparison of Brii Biosciences's Beneish M-Score

For the Biotechnology subindustry, Brii Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Beneish M-Score falls into.



Brii Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Brii Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 126.632+0.528 * 1+0.404 * 1.4713+0.892 * 0.0117+0.115 * 0.6327
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 59.4714+4.679 * 0.131067-0.327 * 0.5747
=103.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$19.12 Mil.
Revenue was HK$0.68 Mil.
Gross Profit was HK$0.68 Mil.
Total Current Assets was HK$3,043.74 Mil.
Total Assets was HK$3,498.18 Mil.
Property, Plant and Equipment(Net PPE) was HK$6.14 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$17.14 Mil.
Selling, General, & Admin. Expense(SGA) was HK$62.46 Mil.
Total Current Liabilities was HK$137.67 Mil.
Long-Term Debt & Capital Lease Obligation was HK$0.00 Mil.
Net Income was HK$-191.22 Mil.
Gross Profit was HK$0.00 Mil.
Cash Flow from Operations was HK$-649.72 Mil.
Total Receivables was HK$12.90 Mil.
Revenue was HK$57.65 Mil.
Gross Profit was HK$57.65 Mil.
Total Current Assets was HK$3,436.02 Mil.
Total Assets was HK$3,787.73 Mil.
Property, Plant and Equipment(Net PPE) was HK$21.80 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$19.02 Mil.
Selling, General, & Admin. Expense(SGA) was HK$89.70 Mil.
Total Current Liabilities was HK$255.85 Mil.
Long-Term Debt & Capital Lease Obligation was HK$3.52 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(19.123 / 0.675) / (12.898 / 57.652)
=28.33037 / 0.223722
=126.632

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(57.652 / 57.652) / (0.675 / 0.675)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3043.744 + 6.135) / 3498.179) / (1 - (3436.018 + 21.801) / 3787.728)
=0.128152 / 0.087099
=1.4713

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.675 / 57.652
=0.0117

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(19.02 / (19.02 + 21.801)) / (17.144 / (17.144 + 6.135))
=0.465937 / 0.736458
=0.6327

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(62.459 / 0.675) / (89.701 / 57.652)
=92.531852 / 1.555904
=59.4714

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 137.673) / 3498.179) / ((3.524 + 255.854) / 3787.728)
=0.039356 / 0.068479
=0.5747

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-191.224 - 0 - -649.72) / 3498.179
=0.131067

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Brii Biosciences has a M-score of 103.06 signals that the company is likely to be a manipulator.


Brii Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences (HKSE:02137) Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines